ALSO NOTED: FDA orders hydrocodone meds off shelves; Novartis gets E.U. approval for Galvus;

> The FDA ordered drug companies to stop making and selling any unapproved medications that contain hydrocodone, including cold remedies and cough syrups. The companies have until October 31 to stop selling the drugs labeled for kids under six and until March 31 to stop shipping any others. Report

> Novartis got the EU's go-ahead to market its type 2 diabetes drug Galvus, which belongs to a new class of meds known as DPP-4 inhibitors. Release

> Bristol-Myers Squibb recruited Jeremy Levin, formerly of Novartis, as its new senior vice president of external science, technology, and licensing. Release

> Wyeth is expanding its stock buyback program to $5 billion and has declared a dividend of 28 cents per share. Release

> GlaxoSmithKline appointed Sir Roy Anderson, a professor of infectious disease epidemiology at Imperial College, London, to its board of directors. Release

And Finally... Here's a future drug-and-diagnostic duo for you. Researchers have flagged two bad-boy genetic variations that may increase the likelihood of suicidal thoughts in patients who start taking antidepressants--which could lead to screening tests to either keep those patients off the drugs, or ensure that they're closely monitored until they get better. Report

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?